Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies ...

Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

Eli Lilly joins up with Camurus to make long-acting versions of the pharma's obesity and diabetes drugs, joining the industry ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

US pharma major Eli Lilly (NYSE: LLY) has struck a deal worth up to $870 million with Swedish biotech Camurus (Nasdaq ...

Although as of this week the stock has declined by more than 4% since the start of the year, there's little reason to believe ...

Welldoc®, a leader in AI-powered digital health innovation, today announced it will power the newly launched Lilly Healthtm Personalized Health & Medicine Platform* (Lilly Health app) with its ...

No drug is without potential side effects, and there are five major ones that people taking Ozempic, Wegovy or Mounjaro are ...

LUND, Sweden and INDIANAPOLIS, IN, USA I June 3, 2025 I Camurus (NASDAQ STO: CAMX) and Eli Lilly and Company ("Lilly") have entered a collaboration and ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.

Over the past decade, the global pharmaceutical industry has witnessed a transformation in the treatment landscape for ...

The cash-based acquisition – the financial terms of which are not being disclosed – will expand Hims & Hers' presence in the ...